Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

SML2237

Sigma-Aldrich

Ormeloxifene

≥95% (HPLC)

Synonym(s):

(trans)-1-[2-[p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy]ethyl]pyrrolidine, 3,4-trans-2,2-Dimethyl-3-phenyl-4-[p-(β-pyrrolidinoethoxy)phenyl]-7-methoxychroman, Centchroman, rel-1-[2-[4-[(3R,4R)-3,4-Dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl]phenoxy]ethyl]pyrrolidine, trans-Centchroman

Sign Into View Organizational & Contract Pricing

Select a Size

25 μL
$179.00
100 μL
$515.00
200 μL
$678.00

$179.00


In StockDetails


Request a Bulk Order

Select a Size

Change View
25 μL
$179.00
100 μL
$515.00
200 μL
$678.00

About This Item

Empirical Formula (Hill Notation):
C30H35NO3
CAS Number:
Molecular Weight:
457.60
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

$179.00


In StockDetails


Request a Bulk Order

assay

≥95% (HPLC)

form

film or powder (or oil)

color

colorless to yellow-white

storage temp.

2-8°C

SMILES string

CC([C@@H](C1=CC=CC=C1)[C@@H]2C3=CC=C(OCCN4CCCC4)C=C3)(C)OC5=C2C=CC(OC)=C5

InChI

1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1

InChI key

XZEUAXYWNKYKPL-WDYNHAJCSA-N

Biochem/physiol Actions

Ormeloxifene (Centchroman) is a non-steroidal selective estrogen receptor modulator (SERM) that exhibit anticancer activity. Ormeloxifene suppresses the ovariectomy-induced bone resorption in rats.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


  • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number

    Sorry, we don't have COAs for this product available online at this time.

    If you need assistance, please contact Customer Support.

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    William R Surin et al.
    Journal of basic and clinical physiology and pharmacology, 1-8 (2014-01-29)
    Abstract Background: Cancer is one of the leading causes of morbidity and mortality globally. Cancer-associated thrombosis is well established in clinical settings, and thrombin has been found to induce angiogenesis at cancer sites. This establishes a link between cardiovascular diseases
    Geetika Kharkwal et al.
    Journal of molecular endocrinology, 48(3), 261-270 (2012-04-12)
    Ormeloxifene (Orm), a triphenylethylene compound, has been established as a selective estrogen receptor modulator (SERM) that suppresses the ovariectomy-induced bone resorption in rats. However, the precise mechanism underlying the bone-preserving action of Orm remains unclear. In this study, we evaluated
    Bilal Bin Hafeez et al.
    Molecular cancer therapeutics, 16(10), 2267-2280 (2017-06-16)
    Ormeloxifene is a clinically approved selective estrogen receptor modulator, which has also shown excellent anticancer activity, thus it can be an ideal repurposing pharmacophore. Herein, we report therapeutic effects of ormeloxifene on prostate cancer and elucidate a novel molecular mechanism

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service